Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Up 1,022.5% in January

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 4,710,000 shares, an increase of 1,022.5% from the December 31st total of 419,600 shares. Based on an average daily trading volume, of 6,840,000 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, Leerink Partners cut their target price on shares of Vincerx Pharma from $80.00 to $40.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

Vincerx Pharma Stock Down 3.8 %

Shares of NASDAQ:VINC traded down $0.06 during trading on Thursday, hitting $1.50. The stock had a trading volume of 985,186 shares, compared to its average volume of 1,223,157. Vincerx Pharma has a 12 month low of $1.40 and a 12 month high of $187.44. The company has a market capitalization of $2.52 million, a PE ratio of -1.46 and a beta of 1.48. The firm’s fifty day moving average is $4.01 and its 200 day moving average is $8.84.

Hedge Funds Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP increased its holdings in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 328,533 shares of the company’s stock after acquiring an additional 256,967 shares during the period. Marshall Wace LLP owned approximately 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.02% of the company’s stock.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.